Drugs / AdCLD-CoV19-1 OMI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05576623 | Sep 2022 → Mar 2023 | COVID-19 | Cellid Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05993325 | Nov 2023 → Mar 2025 overdue | COVID-19 | Cellid Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdCLD-CoV19-1 OMI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05993325 ↗ |
| Modality | Vaccine | “A SARS-CoV-2 (COVID-19) Preventive Vaccine” NCT05576623 ↗ |
| Route | Intramuscular | “via intramuscular injection” NCT05576623 ↗ |